Search Results - "Flörcken, A"

Supportive therapy and complementary medicine in renal cell carcinoma by Johannsen, M., Stoll, C., Raida, M., van Oorschot, B., Flörcken, A.

“…Purpose As part of the German interdisciplinary S3-guideline “Diagnosis, Treatment and Followup of Renal Cell Carcinoma”, this article aimes to provide…”
Get full text

Thrombus or tumor? A case report of a rare sarcoma entity: intimal sarcoma of the pulmonary arteries by Dörr, A., Flörcken, A., Bullinger, L., Capper, D., Deimling, A. Von, Kaul, D., Märdian, S., Starck, C., Horst, D., Dragomir, M.P., Schäfer, F.M., Jarosch, A.

“…Background Tumor embolism is a very rare primary manifestation of cancers and the diagnosis is challenging, especially if located in the pulmonary arteries,…”
Get full text

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis by Brandes, F, Striefler, J K, Dörr, A, Schmiester, M, Märdian, S, Koulaxouzidis, G, Kaul, D, Behzadi, A, Thuss-Patience, P, Ahn, J, Pelzer, U, Bullinger, L, Flörcken, A

“…Soft tissue sarcomas (STS) account for less than 1% of all malignancies. Approximately 50% of the patients develop metastases with limited survival in the…”
Get full text

Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy by Johannsen, M., Staehler, M., Ohlmann, C.-H., Flörcken, A., Schmittel, A., Otto, T., Bex, A., Hein, P., Miller, K., Weikert, S., Grünwald, V.

“…It is unknown if discontinuation of targeted therapy (TT) and readministration in case of recurrence is feasible in patients with metastatic renal cell…”
Get full text

Allogeneic gene-modified tumor cells (RCC-26 IL-7 CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study by Westermann, J, Flörcken, A, Willimsky, G, van Lessen, A, Kopp, J, Takvorian, A, Jöhrens, K, Lukowsky, A, Schönemann, C, Sawitzki, B, Pohla, H, Frank, R, Dörken, B, Schendel, D J, Blankenstein, T, Pezzutto, A

“…Despite novel targeted agents, prognosis of metastatic renal cell cancer (RCC) remains poor, and experimental therapeutic strategies are warranted…”
Get full text

Introduction of a ketogenic diet in young infants by Klepper, J., Leiendecker, B., Bredahl, R., Athanassopoulos, S., Heinen, F., Gertsen, E., Flörcken, A., Metz, A., Voit, T.

“…The ketogenic diet is a rational treatment for pyruvate dehydrogenase complex deficiency (McKusick 312170) and GLUT1 deficiency syndrome (McKusick 138140). An…”
Get full text

679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH) by Darr, C., Zschäbitz, S., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Müller, L., Metz, M., Bergmann, L., Steiner, T., Lorch, A., Schütt, P., Rafiyan, M-R., Hellmis, E., Hinke, A., Mänz, M., Meiler, J., Kretz, T., Flörcken, A., Grünwald, V.

Get full text

1553TiP A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma by Schliemann, C., Pink, D., Flörcken, A., Ahrens, M., Egerer, G., Götze, K., Palmerini, E., Stacchiotti, S., Grignani, G., Rutkowski, P., Ullrich, R., Strapatsas, J., Hemmerle, T., Neri, D., Kessler, T.

Get full text

959P - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

“…Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC). We tested if TKI…”
Get full text

A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

Get full text

959PA phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V, Grüllich, C, Ivanyi, P, Wirth, M, Staib, P, Schostak, M, Dargatz, P, Müller, L, Metz, M, Bergmann, L, Welslau, M K, Schütt, P, Rafiyan, M-R, Hellmis, E, Hinke, A, Meiler, J, Kretz, T, Loidl, W C, Flörcken, A, Steiner, T

“…Abstract Background Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC)…”
Get full text

Autosomal dominant transmission of GLUT1 deficiency by KLEPPER, Jörg, WILLEMSEN, Michèl, VERRIPS, Aad, GUERTSEN, Elena, HERRMANN, Ralf, KUTZICK, Christian, FLÖRCKEN, Anne, VOIT, Thomas

“…GLUT1 deficiency is caused by a defect in the facilitative glucose transporter GLUT1. Impaired glucose transport across brain tissue barriers is reflected by…”
Get full text

Sarcoma Patients Admitted to the Intensive Care Unit (ICU): Predictive Relevance of Common Sepsis and Performance Parameters by Striefler, Jana K, Binder, Phung T, Brandes, Franziska, Rau, Daniel, Wittenberg, Silvan, Kaul, David, Roohani, Siyer, Jarosch, Armin, Schäfer, Frederik M, Öllinger, Robert, Märdian, Sven, Bullinger, Lars, Eckardt, Kai-Uwe, Kruse, Jan, Flörcken, Anne

“…Prognosis of sarcoma patients is improving, with a better understanding of sarcomagenesis revealing novel therapeutic targets. However, aggressive chemotherapy…”
Get full text

Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis by Casper, J., Goebel, D., Gruenwald, V., Flörcken, A., Mueller, D., Toussaint, K., Metzner, B.

“…Abstract only…”
Get full text

Effects of anticonvulsants on GLUT1-mediated glucose transport in GLUT1 deficiency syndrome in vitro by KLEPPER, Jörg, FLÖREKEN, Anne, FISCHBARG, Jorge, VOIT, Thomas

“…Facilitative type-1 glucose transporter (GLUT1) deficiency syndrome is caused by a defect of glucose transport into brain, resulting in an epileptic…”
Get full text